Physician profile
Eric M Schlueter
NPI 1629020037
$1,127.59
in general payments reported to CMS, 2019-2025
21 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.08 · 2020: $11.35 · 2021: $65.79 · 2022: $234 · 2023: $240 · 2024: $212 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738 · Entertainment: $13.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.19 |
| Entertainment | $13.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $186.14 | 2022-2025 | Breztri, Airsupra |
| Pfizer INC. | $177.01 | 2019-2025 | |
| Exact Sciences Corporation | $151.12 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $141.84 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Viiv Healthcare Company | $90.41 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $45.00 | 2024 | |
| Sanofi Pasteur INC. | $40.80 | 2019-2023 | |
| Glaxosmithkline, LLC. | $39.84 | 2019-2025 | Arexvy, Shingrix, Penmenvy |
| Dexcom, INC. | $33.48 | 2025 | Dexcom G6 Transmitter |
| Stryker Corporation | $31.30 | 2025 | Clottriever Bold Catheter |
| Recor Medical INC | $24.84 | 2025 | Paradise Ultrasound Renal Denervation System |
| Masimo Corporation | $24.48 | 2022 | |
| Edwards Lifesciences Corporation | $20.26 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.17 | 2024 | Xifaxan |
| Tris Pharma INC | $17.49 | 2025 | Dyanavel Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.27 | 2023 | Proquad, Vaxneuvance, Gardasil 9 |
| Lilly USA, LLC | $16.40 | 2024 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $14.35 | 2023 | Quviviq |
| Optos, INC. | $13.66 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Napo Pharmaceuticals INC | $12.01 | 2019 | |
| Abbvie INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Schlueter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.